liver-disease
(3)
Vincent Ling
Vincent Ling is the Chief Business Officer of Morphocell Technologies, a Laval-based regenerative medicine company building iPSC-derived engineered tissues to treat severe organ dysfunction, starting with liver disease. A biotech and pharma veteran of three decades, he spent 12 years at Takeda's Center for External Innovation, where he identified and backed the Kariko-Weissman mRNA platform out of the University of Pennsylvania - the science that became the first COVID mRNA vaccines and earned the 2023 Nobel Prize. He has held leadership roles at Genetics Institute, Adnexus Therapeutics, and Neurotech Pharmaceuticals, and advises the Gates Foundation and academic institutions.
John McHutchison
John McHutchison, AO, MD is the CEO and Chairman of Tune Therapeutics, a pioneering epigenome editing company based in Durham, NC. An internationally acclaimed hepatologist and drug developer, McHutchison spent nearly a decade at Gilead Sciences as Chief Scientific Officer, where he led the development of transformative hepatitis C cures used by over 3.2 million people worldwide, including Sovaldi and Harvoni. Now at Tune, he is steering the company's TEMPO epigenome editing platform toward a new era of precision medicine for chronic and complex diseases.
Diana Peng Bockus
Diana Peng Bockus is the Chief Executive Officer of NGM Biopharmaceuticals, a South San Francisco biotech developing first-in-class medicines for liver disease, oncology, and ophthalmology. Appointed CEO in April 2025, she joined the company in 2020 to lead business development and restructured a pivotal Merck partnership that freed NGM to build a wholly owned pipeline. A Stanford and Wharton graduate with roots in management consulting at Bain & Company, she now steers a privately held biotech backed by $515M in total funding, focused on rare diseases like primary sclerosing cholangitis and hyperemesis gravidarum.